United Therapeutics Corporation Deferred Federal Income Tax Expense (Benefit)
United Therapeutics Corporation (UTHR) reported Deferred Federal Income Tax Expense (Benefit) of $85.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-02-25
- United Therapeutics Corporation deferred federal income tax expense (benefit) for fiscal 2025 was $85.70M.
- United Therapeutics Corporation deferred federal income tax expense (benefit) for fiscal 2024 was -$56.70M.
- United Therapeutics Corporation deferred federal income tax expense (benefit) for fiscal 2023 was -$43.80M.
- United Therapeutics Corporation deferred federal income tax expense (benefit) for fiscal 2022 was -$44.80M.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month | Deferred Federal Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | $85.70M 10-K · filed 2026-02-25 | |
| 2024-12-31 | -$56.70M 10-K · filed 2026-02-25 | |
| 2023-12-31 | -$43.80M 10-K · filed 2026-02-25 | -$44.30M 10-K · filed 2024-02-21 |
| 2022-12-31 | -$44.80M 10-K · filed 2025-02-26 | |
| 2021-12-31 | -$10.10M 10-K · filed 2024-02-21 | |
| 2020-12-31 | $1.60M 10-K · filed 2023-02-22 | |
| 2019-12-31 | -$120.10M 10-K · filed 2022-02-24 | |
| 2018-12-31 | $12.70M 10-K · filed 2021-02-24 | |
| 2017-12-31 | $67.20M 10-K · filed 2020-02-26 | |
| 2016-12-31 | $8.30M 10-K · filed 2019-02-27 | |
| 2015-12-31 | -$2.70M 10-K · filed 2018-02-21 | -$2.85M 10-K · filed 2016-02-25 |
| 2014-12-31 | -$3.10M 10-K · filed 2017-02-22 | -$2.94M 10-K · filed 2015-02-24 |
| 2013-12-31 | -$37.71M 10-K · filed 2016-02-25 | |
| 2012-12-31 | $37.26M 10-K · filed 2015-02-24 | |
| 2011-12-31 | $11.23M 10-K · filed 2014-02-25 | |
| 2010-12-31 | -$1.61M 10-K · filed 2013-02-26 | |
| 2009-12-31 | -$24.40M 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |